In our study, 80.7% of patients were diagnosed with stage III-IV lung cancer, and EGFR mutation status was incorporated into the multivariate analysis and identified as an independent prognostic factor for patients with lung cancer and ILA, after excluding those with subpleural fibrotic ILA. Here, EGFR is linked to lung cancer.